Pharmocann Global Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Pharmocann Global has been growing earnings at an average annual rate of 15.6%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been declining at an average rate of 9.1% per year.
Anahtar bilgiler
15.6%
Kazanç büyüme oranı
40.5%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 35.1% |
Gelir büyüme oranı | -9.1% |
Özkaynak getirisi | -4,587.4% |
Net Marj | -76.1% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
The Returns On Capital At Pharmocann Global (TLV:PMCN) Don't Inspire Confidence
Mar 30Should You Use Pharmocann Global's (TLV:PMCN) Statutory Earnings To Analyse It?
Feb 04Pharmocann Global Ltd (TLV:PMCN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Dec 31The Returns At Pharmocann Global (TLV:PMCN) Provide Us With Signs Of What's To Come
Nov 26Gelir ve Gider Dağılımı
Pharmocann Global nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 13 | -10 | 8 | 0 |
31 Mar 24 | 14 | -10 | 8 | 0 |
31 Dec 23 | 14 | -10 | 8 | 0 |
30 Sep 23 | 11 | -12 | 6 | 0 |
30 Jun 23 | 12 | -18 | 7 | 1 |
31 Mar 23 | 17 | -24 | 10 | 1 |
31 Dec 22 | 23 | -25 | 13 | 1 |
30 Sep 22 | 24 | -23 | 12 | 1 |
30 Jun 22 | 25 | -20 | 13 | 1 |
31 Mar 22 | 28 | -16 | 15 | 1 |
31 Dec 21 | 29 | -19 | 15 | 1 |
30 Sep 21 | 31 | -14 | 15 | 1 |
30 Jun 21 | 32 | -7 | 15 | 1 |
31 Mar 21 | 31 | 2 | 13 | 1 |
31 Dec 20 | 28 | 4 | 13 | 1 |
30 Sep 20 | 26 | 6 | 11 | 1 |
30 Jun 20 | 26 | 5 | 10 | 1 |
31 Mar 20 | 21 | -25 | 9 | 1 |
31 Dec 19 | 21 | -46 | 6 | 1 |
30 Sep 19 | 18 | -46 | 6 | 0 |
30 Jun 19 | 17 | -46 | 4 | 0 |
31 Mar 19 | 16 | -20 | 4 | 0 |
31 Dec 18 | 15 | 6 | 3 | 0 |
31 Dec 17 | 12 | 2 | 3 | 0 |
31 Dec 16 | 9 | 1 | 2 | 0 |
Kaliteli Kazançlar: PMCN-M is currently unprofitable.
Büyüyen Kar Marjı: PMCN-M is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: PMCN-M is unprofitable, but has reduced losses over the past 5 years at a rate of 15.6% per year.
Büyüme Hızlandırma: Unable to compare PMCN-M's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: PMCN-M is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7.1%).
Özkaynak Getirisi
Yüksek ROE: PMCN-M has a negative Return on Equity (-4587.44%), as it is currently unprofitable.